Related Experiment Video

Updated: Jul 6, 2026

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

Cetuximab for colorectal cancer

Feng Yang, Deliang Fu, Quanxing Ni

    The New England Journal of Medicine
    |March 14, 2008
    PubMed
    Summary

    No abstract available in PubMed .

    More Related Videos

    Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer
    08:12

    Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer

    Published on: March 14, 2019

    Related Experiment Videos

    Last Updated: Jul 6, 2026

    Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
    09:29

    Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

    Published on: September 30, 2016

    Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer
    08:12

    Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer

    Published on: March 14, 2019

    Related Concept Videos

    Targeted Cancer Therapies02:57

    Targeted Cancer Therapies

    The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
    There are several types of targeted therapies against specific...
    Treatment Resistent Cancers02:56

    Treatment Resistent Cancers

    Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

    Articles linked to this work by shared authors, journal, and citation graph.

    Parenchyma-sparing pancreatectomy for solid pseudopapillary neoplasm of the pancreas: A propensity-matched analysis.

    Surgery·2026

    HRD Score: A Promising Biomarker for Genomic Instability Evaluation for Targeted Treatments Among Pancreatic Cancer Patients.

    Technology in cancer research & treatment·2026

    Extracellular vesicles from chemotherapy-induced senescent tumor cells reprogram hepatic phospholipid metabolism to promote pancreatic cancer liver metastasis.

    Journal of experimental & clinical cancer research : CR·2026

    Unraveling the Two-Stage Phase Evolution Mechanism of Deep Lacustrine Type I Kerogen: Integrated Insights from Pyrolysis Kinetics, Isotopic Fingerprinting, and PVT Modeling.

    ACS omega·2026

    Tecotabart vedotin in Claudin 18.2-positive advanced gastric/gastroesophageal junction cancer: A Bayesian phase 1/2 clinical trial.

    European journal of cancer (Oxford, England : 1990)·2025

    Phase 1 trial of HR070803 (an Irinotecan liposome) in combination with 5-fluorouracil, leucovorin, and oxaliplatin for untreated advanced or metastatic pancreatic ductal adenocarcinoma.

    BMC medicine·2025

    Syncope.

    The New England journal of medicine·2026

    An NLRP3 inflammasome inhibitor evoked dose-dependent anti-allodynia in the hindpaws of a rat model of chemotherapy-induced peripheral neuropathy.

    Inflammopharmacology·2026

    BE-BOIN: A Dose Optimization Design Accommodating Backfill and Late-Onset Toxicity.

    Therapeutic innovation & regulatory science·2026

    OCT4 modulates Pomc gene transcription by interfering with specific corticotroph transcription factors.

    Journal of endocrinological investigation·2026

    Inherently Therapeutic Plasmalogen-Based Nanoparticle Platform to Kill Ovarian Cancer Cells via Synergistic Ferroptosis Induction.

    ACS biomaterials science & engineering·2026

    Neurocognitive functioning of patients treated for pediatric craniopharyngioma and predictors of outcomes.

    Child neuropsychology : a journal on normal and abnormal development in childhood and adolescence·2026

    GLUT-Mediated Uptake of Glyco-Trojan Horse Enables Targeted PDT for Breast Cancer.

    Biomacromolecules·2026
    See all related articles
    JoVE
    x logofacebook logolinkedin logoyoutube logo
    ABOUT JoVE
    OverviewLeadershipBlogJoVE Help Center
    AUTHORS
    Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
    LIBRARIANS
    TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
    RESEARCH
    JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
    EDUCATION
    JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
    Terms & Conditions of Use
    Privacy Policy
    Policies
    Jove
    Visualize
    Contact Us